MicroRNAs associated with PCa therapy.
References Sample type Therapy miRs deregulated miRs selected as candidates Josson et al. (2008) [ 107] LnCaP and LnCaP C4-2B Radiation therapy 6 downregulated miR-521 ↓ Huang et al. (2013) [ 110] PC3 radiation resistant cells Radiation therapy 1 upregulated miR-95 ↑ Ribas et al. (2009) [ 85] LNCaP and LAPC-4 Hormone therapy Overexpressed miR-21 ↑ Ottman et al. (2014) [ 113] LnCap CDX sensitive cells LnCap CDX non-sensitive cells Androgen deprivation-therapy and casodex 21 upregulated 22 downregulated http://www.molecularcancer.com /content/13/1/1
Lehmusvaara et al. (2013) [ 114] 28 tumor tissues ( goserelin-treated patients bicalutamide-treated patients no treated-patients)
miR-9 and miR-17
↓ Zhang et al. (2011) [ 88] Serum samples from localized PCa ( ), ADPC ( ), CRPC DTX treated ( ) and BPH ( ) Docetaxel 1 upregulated miR-21 (in CRPC docetaxel resistant) ↑ Puhr et al. (2012) [ 116] PC3 docetaxel-resistant cells Docetaxel 2 downregulated miR-200c, miR-205 ↓
Lin et al. (2014) [ 118] Serum and plasma samples from CRPC PCa ( ) before and after therapy Docetaxel 46 deregulated miR-200c, miR-200b, miR-146a, miR-222, miR-301b, miR-20a Kojima et al. (2010) [ 119] PC3 paclitaxel-resistant cells Paclitaxel 1 downregulated miR-34a ↓ Fujita et al. (2010) [ 121] PC3 and DU145 Paclitaxel 1 downregulated miR-148 ↓ PCa: prostate cancer; ADPC: androgen dependent prostate cancer; CRPC: castration resistant prostate cancer; BPH: benign prostatic hyperplasia; DTX: docetaxel; CDX: casodex.